Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer

• Status: Terminated
• Trial end date: 2004-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess safety, efficacy and explorative objectives of gefitinib in combination with chemoradiation in resectable gastric cancer

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Fluorouracil; Gefitinib; Leucovorin

Criteria

Inclusion Criteria:

• Histologically-confirmed intestinal GC (T2-T4)

• Local or locally advanced stage II or stage III gastric cancer of an upper part of the stomach or GE junction

• Lymph node positive or negative

• Metastasis negative

• Resection with curative intent (R0, D2)

• Chemo- and radiotherapy naïve

• Measurable lesion according RECIST

• Written informed consent

Exclusion Criteria:

• Aged below 45 or over 70

• Prior gastric surgery

• Active ILD